Ubrogepant
Brand names: Ubrelvy
At a glance
- Medicare prescriptions, 2024
- 234,370
- Medicare drug cost
- $305.5M
- Average cost per prescription
- $1,303
- Clinicians who prescribed it
- 7,368
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
UBRELVY is indicated for the acute treatment of migraine with or without aura in adults.
From the FDA-approved prescribing information (label dated June 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Neurology 46.6%
- Nurse Practitioners 26.6%
- Physician Assistants 11.4%
- Family Medicine 5.6%
- Internal Medicine 3.8%
- Pain Medicine 2.2%
- Physical Medicine & Rehabilitation (PM&R) 0.9%
- Child Neurology 0.4%
- Psychiatry 0.3%
- General Practice 0.2%
- Neurosurgery 0.2%
- Anesthesiology 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2020–2024
Medicare prescriptions rose 604% from 2020 to 2024.
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Allergan, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white capsule, 15 mm | U 50 |
| 100 mg | white capsule, 19 mm | U 100 |
Sportpharm LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white capsule, 15 mm | U 50 |
| 100 mg | white capsule, 19 mm | U 100 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $9.6M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- AbbVie Inc. $9.6M
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Industry-funded trials
- Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine Active, not recruiting · AbbVie Inc.
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) Recruiting · AbbVie Inc.
- Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17) Enrolling by invitation · AbbVie Inc.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.